Celgene Corporation (NASDAQ:CELG) Bank of America Merrill Lynch Healthcare Conference Call May 16, 2018 1:00 PM ET
Executives
Peter Kellogg - Chief Financial Officer
Analysts
Ying Huang - Bank of America Merrill Lynch
Ying Huang
I guess we should get started. My name is Ying Huang, and I’m the Senior Analyst covering at U.S. Biotech here at BofA Merrill Lynch. Our next presenting company is Celgene. We're very pleased to have Peter Kellogg, CFO; and then Jon Biller from Tax and Treasurer; and also, Patrick Flanigan from Investor Relations. So, with that, let me welcome Peter, who will have some prepared remarks, and then we'll go into fireside chat. Thank you, Peter.
Peter Kellogg
Thank you, Ying, and good morning, everybody. It's good to see a lot of familiar faces here. I'd like to start obviously with the standard slide, which is that we obviously be making some forward-looking statements, and that we have guidance and so forth outstanding, and that's all done under the framework of safe harbor, and we do encourage everybody to read all of our SEC filings.
The vision for Celgene and the mission hasn't changed. We remain dedicated to making a real difference in healthcare and while we’ve talked about building a preeminent global biopharmaceutical company for a long time, it has always been on the focus of really innovative therapies and make a huge difference. And that always builds towards a great value proposition in the marketplace, and in fact we’re very proud of the value that has been presented by all of our drugs from REVLIMID to POM to ABRAXANE to OTEZLA and others that are in our late stage pipeline. They really have made a huge difference for patients and of course in the world of healthcare that is evolving as you – is currently going on, I think it’s actually great to be in the position where your drugs represent such enormous value for multiple myeloma patients, for psoriasis patients and so forth, so, and pancreatic cancer patients.
So, I think that will continue to be our focus. We will be always focused on the leading-edge products and we will talk more about that later. Our portfolio obviously is one that is focused first of all on the commercial assets that we have in a lot of our late stage assets really executing against those. I’ll talk in a minute about our first quarter results, which were, I think quite good. We were very pleased with them. We are heading off to, what appear to be a very good 2018 based on those results. But the same time, we are focused on accelerating our pipeline, continue to add to that pipeline to make a really big difference after 2020, and then beyond that we’re always looking for opportunities to push science forward in areas where we have really good capabilities and that would be to expand our portfolio and you’ve seen us do a number of transactions where we are opening up our arsenal, if you will in terms of the acquisition of Juno, we're picking up impact. We did the Beijing deal end of last summer.
